A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

This early-phase study is testing a new experimental drug called GNC-077 in patients with locally advanced or metastatic (spread) breast cancer and other solid tumors. Researchers want to find out whether it is safe, how the body handles it, and whether it has any tumor-shrinking effects. **You may be eligible if...** - You are between 18 and 75 years old (or 18 and older for the expansion phase) - You have locally advanced or metastatic breast cancer or another solid tumor - You have at least one measurable tumor on scans - You are in reasonably good health with adequate blood counts, kidney, and liver function - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have significant bleeding disorders or abnormal blood clotting - Your organs (bone marrow, liver, kidneys) are not functioning adequately - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.